News Focus
News Focus
icon url

Jackxkr

01/17/25 3:15 PM

#744276 RE: CrashOverride #744275

Pinpoint # @$42 ( why not $40) and a rounded off # at $100 . Friday afternoon bourbons kickin in.
icon url

exwannabe

01/17/25 3:21 PM

#744280 RE: CrashOverride #744275

We will be over $100 in 5 years, or even a lot sooner, considering rapid tumor shrinkage trials.


Tumor shrinkage (ORR) is a very normal endpoint in early stage trials. When DCVax has failed to ever show any, longs said it does not matter. And now you cheer it. See anything wrong here?

Management can divide up indications among BP partners then run a bunch of quick trials in parallel.


Having multiple vendors is a great idea for keeping prices reasonable. Maybe the FDA should require it. Not sure why any BP (or smaller player) would want it though.

With Flaskworks in place the greenfield market will be quickly cornered by DCVax


There have been several automated cellular manufacturing systems from vendors in operation for a few years now. Flaskworks Eden, it it ever exists, is a "me too".
icon url

Riley4

01/17/25 3:49 PM

#744288 RE: CrashOverride #744275

Once they start listing options on this I plan to really grow my account for generational wealth. This will be Tesla type moves if they don’t sell out, then will only be one generation wealth, I can live with either as always beating cancer main goal